Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › Efinopegdutide

Efinopegdutide

GLP-1/GCG · s.c. · MSD (Hanmi)

Data cut 12 November 2026 · page built 16 November 2026 · 0 trial arms · 1 trials with results · 4 registered trials · see on the pipeline board

Summary

Also known as
MK-6024
Mechanism
GLP-1/GCG
Route
s.c.
Company
MSD (Hanmi)
Highest development stage
phase 2
Status (as of data cut)
Phase 2b MASH verify
Next milestone
Phase 3 MASH

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity0 no data
T2D0 no data
CV outcomes0 no data
CKD0 no data
HFpEF0 no data
MASH1 phase 2 / signalPositive phase 2b (Lancet, Nov 2026)Phase 2b, Lancet 2026
Sleep apnoea0 no data
Knee OA0 no data
Alzheimer's0 no data

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

Trial arms: weight, HbA1c and tolerability

No trial arms with extracted efficacy or tolerability data yet.

Outcome trials

Other indications

Phase 2b Efinopegdutide · MASH F2–F3 · 52 weeks · n = 386 abstract

MASH resolution without worsening of fibrosis +43.0 / +49.5 / +47.8 percentage points vs placebo (4 / 7 / 10 mg); fibrosis improvement +21.7 / +30.4 / +13.0 (10 mg not significant). Open-label semaglutide 2.4 mg arm: 53 % and 25 %.

MeasureDrugControlDifference (95 % CI)Status
MASH resolution without worsening of fibrosis 4 mg
week 52
+56.0+13.0+43.0 (+25.7 to +57.8) percentage pointsabstract
MASH resolution without worsening of fibrosis 7 mg
week 52
+63.0+13.0+49.5 (+31.4 to +64.2) percentage pointsabstract
MASH resolution without worsening of fibrosis 10 mg
week 52
+61.0+13.0+47.8 (+30.7 to +62.0) percentage pointsabstract
Fibrosis improvement (≥1 stage) without worsening of steatohepatitis 4 mg
week 52
+43.0+21.0+21.7 (+7.1 to +35.7) percentage pointsabstract
Fibrosis improvement (≥1 stage) without worsening of steatohepatitis 7 mg
week 52
+52.0+21.0+30.4 (+15.4 to +44.3) percentage pointsabstract
Fibrosis improvement (≥1 stage) without worsening of steatohepatitis 10 mg
week 52
+34.0+21.0+13.0 (−1.2 to +26.8) percentage pointsabstract
Verbatim quotes (6)
  • MASH resolution without worsening of fibrosis
    difference vs placebo 43·0 percentage points [95% CI 25·7 to 57·8; p<0·0001] for 4 mg, 49·5 percentage points [31·4 to 64·2; p<0·0001] for 7 mg, and 47·8 percentage points [30·7 to 62·0; p<0·0001] for 10 mg
  • MASH resolution without worsening of fibrosis
    difference vs placebo 43·0 percentage points [95% CI 25·7 to 57·8; p<0·0001] for 4 mg, 49·5 percentage points [31·4 to 64·2; p<0·0001] for 7 mg, and 47·8 percentage points [30·7 to 62·0; p<0·0001] for 10 mg
  • MASH resolution without worsening of fibrosis
    difference vs placebo 43·0 percentage points [95% CI 25·7 to 57·8; p<0·0001] for 4 mg, 49·5 percentage points [31·4 to 64·2; p<0·0001] for 7 mg, and 47·8 percentage points [30·7 to 62·0; p<0·0001] for 10 mg
  • Fibrosis improvement (≥1 stage) without worsening of steatohepatitis
    difference vs placebo 21·7 percentage points [7·1 to 35·7; p=0·0038] in the efinopegdutide 4 mg group, 30·4 percentage points [15·4 to 44·3; p<0·0001] in the efinopegdutide 7 mg group, and 13·0 percentage points [-1·2 to 26·8; p=0·072] in the efinopegdutide 10 mg group
  • Fibrosis improvement (≥1 stage) without worsening of steatohepatitis
    difference vs placebo 21·7 percentage points [7·1 to 35·7; p=0·0038] in the efinopegdutide 4 mg group, 30·4 percentage points [15·4 to 44·3; p<0·0001] in the efinopegdutide 7 mg group, and 13·0 percentage points [-1·2 to 26·8; p=0·072] in the efinopegdutide 10 mg group
  • Fibrosis improvement (≥1 stage) without worsening of steatohepatitis
    difference vs placebo 21·7 percentage points [7·1 to 35·7; p=0·0038] in the efinopegdutide 4 mg group, 30·4 percentage points [15·4 to 44·3; p<0·0001] in the efinopegdutide 7 mg group, and 13·0 percentage points [-1·2 to 26·8; p=0·072] in the efinopegdutide 10 mg group

Registered trials (4)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
MK-6024-017
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
MASHPhase 2completed2024-07 → 2026-0885Completed; results not in the atlas yetNCT06465186
MK-6024-016
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)
MASHPhase 2completed2024-07 → 2025-06124Completed; results not in the atlas yetNCT06482112
Phase 2b
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
CV outcomesPhase 2completed2023-06 → 2025-12381Completed; results not yet publicNCT05877547
MK-6024-001
A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)
MASHPhase 2completed2021-08 → 2022-10145Completed; results not in the atlas yetNCT04944992

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Efinopegdutide. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/efinopegdutide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.